BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen XQ, Salehi A, Pearn ML, Overk C, Nguyen PD, Kleschevnikov AM, Maccecchini M, Mobley WC. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement 2021;17:271-92. [PMID: 32975365 DOI: 10.1002/alz.12185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Overk C, Mobley WC. Down syndrome: a model for chromosome abnormalities. Neurobiology of Brain Disorders 2023. [DOI: 10.1016/b978-0-323-85654-6.00007-1] [Reference Citation Analysis]
2 Kleschevnikov AM. Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits. Front Genet 2022;13:1006068. [DOI: 10.3389/fgene.2022.1006068] [Reference Citation Analysis]
3 Farrell C, Mumford P, Wiseman FK. Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches. Front Neurosci 2022;16:909669. [DOI: 10.3389/fnins.2022.909669] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Stagni F, Bartesaghi R. The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives. Front Cell Neurosci 2022;16:903729. [DOI: 10.3389/fncel.2022.903729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Hurley D. Memantine Fails to Improve Cognition in Down Syndrome. Neurology Today 2022;22:26-27. [DOI: 10.1097/01.nt.0000819860.80255.c3] [Reference Citation Analysis]
6 Batool S, Furqan T, Hasan Mahmood MS, Tweedie D, Kamal MA, Greig NH. In Silico and Ex Vivo Analyses of the Inhibitory Action of the Alzheimer Drug Posiphen and Primary Metabolites with Human Acetyl- and Butyrylcholinesterase Enzymes. ACS Pharmacol Transl Sci . [DOI: 10.1021/acsptsci.1c00200] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Bartesaghi R, Vicari S, Mobley WC. Prenatal and Postnatal Pharmacotherapy in Down Syndrome: The Search to Prevent or Ameliorate Neurodevelopmental and Neurodegenerative Disorders. Annu Rev Pharmacol Toxicol 2022;62:211-33. [PMID: 34990205 DOI: 10.1146/annurev-pharmtox-041521-103641] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wu T, Lin D, Cheng Y, Jiang S, Riaz MW, Fu N, Mou C, Ye M, Zheng Y. Amyloid Cascade Hypothesis for the Treatment of Alzheimer’s Disease: Progress and Challenges. Aging and disease 2022;13:1745. [DOI: 10.14336/ad.2022.0412] [Reference Citation Analysis]
9 Yao Z, Fu L, Jia F, Bi M, Jiao Q, Chen X, Du X, Jiang H. Rethinking IRPs/IRE system in neurodegenerative disorders: Looking beyond iron metabolism. Ageing Res Rev 2022;73:101511. [PMID: 34767973 DOI: 10.1016/j.arr.2021.101511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chen XQ, Barrero CA, Vasquez-Del Carpio R, Reddy EP, Fecchio C, Merali S, Deglincerti A, Fang C, Rogers J, Maccecchini ML. Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression. Pharmaceutics 2021;13:2109. [PMID: 34959389 DOI: 10.3390/pharmaceutics13122109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sawa M, Overk C, Becker A, Derse D, Albay R, Weldy K, Salehi A, Beach TG, Doran E, Head E, Yu YE, Mobley WC. Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model. Alzheimers Dement 2021. [PMID: 34757693 DOI: 10.1002/alz.12463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Chen XQ, Xing Z, Chen QD, Salvi RJ, Zhang X, Tycko B, Mobley WC, Yu YE. Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome. Front Aging Neurosci 2021;13:700280. [PMID: 34276349 DOI: 10.3389/fnagi.2021.700280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Ferrari M, Stagi S. Oxidative Stress in Down and Williams-Beuren Syndromes: An Overview. Molecules 2021;26:3139. [PMID: 34073948 DOI: 10.3390/molecules26113139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Chen XQ, Das U, Park G, Mobley WC. Normal levels of KIF5 but reduced KLC1 levels in both Alzheimer disease and Alzheimer disease in Down syndrome: evidence suggesting defects in anterograde transport. Alzheimers Res Ther 2021;13:59. [PMID: 33691783 DOI: 10.1186/s13195-021-00796-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Checler F, Afram E, Pardossi-Piquard R, Lauritzen I. Is γ-secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99? J Biol Chem 2021;296:100489. [PMID: 33662398 DOI: 10.1016/j.jbc.2021.100489] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
16 Chen XQ. A pilot exploration with Posiphen to normalize amyloid precursor protein in Down syndrome. Neural Regen Res 2021;16:2420-1. [PMID: 33907026 DOI: 10.4103/1673-5374.313044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Chen XQ, Salehi A, Pearn ML, Overk C, Nguyen PD, Kleschevnikov AM, Maccecchini M, Mobley WC. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model. Alzheimers Dement 2021;17:271-92. [PMID: 32975365 DOI: 10.1002/alz.12185] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]